Citizens Highlights BeOne Medicines' (ONC) $3.8B Revenue Potential for 2025 [Yahoo! Finance]
BeOne Medicines Ltd. - American Depositary Shares (ONC)
Company Research
Source: Yahoo! Finance
rating and $396 price target for BeOne Medicines Ltd. (NASDAQ:ONC), citing strong effectiveness results from a Phase 3 trial in gastric cancer patients. BeOne Medicines Ltd. (NASDAQ:ONC) and Jazz Pharmaceutics shared further findings from the HERIZON-GEA-01 trial, which revealed high efficacy in patients with advanced gastric or gastroesophageal adenocarcinoma (GEA). Citizens observed that BeOne's Brukinsa was on track to generate about $3.8 billion in revenue in 2025, thanks to an impressive development pipeline that includes numerous assets across diverse indications. The company also revealed the first clearance for sonrotoclax, its next-generation BCL2 inhibitor, which Citizens anticipates could contribute to subsequent approvals worldwide. At the same time, the firm emphasized BeOne's $4.1 billion cash position and stated that the recent share price decline represented a “unique buying opportunity” in one of the world's leading hematology/oncology companies. BeOne Medicin
Show less
Read more
Impact Snapshot
Event Time:
ONC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONC alerts
High impacting BeOne Medicines Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ONC
News
- BeOne Medicines (NASDAQ:ONC) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
- BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- BeOne Medicines (NASDAQ:ONC) was upgraded by analysts at Sanford C. Bernstein to an "outperform" rating.MarketBeat
- BeOne Medicines (NASDAQ:ONC) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEABusiness Wire
ONC
Earnings
- 11/6/25 - Beat
ONC
Sec Filings
- 1/9/26 - Form 4
- 1/5/26 - Form 4
- 12/17/25 - Form 4
- ONC's page on the SEC website